SureTrader
Cannabis Stocks News
Interactive Brokers Advertisement
Home > Boards > US Listed > Biotechs >

BioLineRx Ltd. (BLRX)

BLRX RSS Feed
Add BLRX Price Alert      Hide Sticky   Hide Intro
Moderator: midastouch017
Search This Board: 
Last Post: 8/16/2017 1:02:37 PM - Followers: 91 - Board type: Free - Posts Today: 6

BIOLINERX
BioLineRx is a clinical-stage, publicly-traded (NASDAQ/ TASE: BLRX) biopharmaceutical development company based in Jerusalem, Israel.
The Company develops products suitable for the pharmaceutical market satisfying an unmet medical need or exhibiting advantages over current therapies.

BioLineRx's close ties with universities, research institutes, academic institutions, technology transfer offices and biotechnology companies, both in Israel and globally, enable access to promising projects at an early stage. The first stage involves a stringent selection process. BioLineRx's scientists specialize in evaluating potential drug candidates from both scientific and marketing perspectives. After acquiring the most promising projects, the Company then performs feasibility assessment studies and development through pre-clinical and clinical stages. Supported and assisted by a distinguished panel of scientific advisers, the Company's scientists and experts in pharmacy and regulation, clinical trials and IP work together to advance BioLineRx’s pipeline usually through Phase II proof of concept in humans. And finally, the Company partners with medium size and large pharmaceutical companies to complete the clinical development and bring the product to market.
 
BioLineRx also operates BioLine Innovations Jerusalem (BIJ) a biotechnology incubator for the development of pre-clinical therapeutic candidates, and an Early Development Program (EDP) dedicated to identifying and advancing promising early stage programs.

==============================

HIGHLIGHTS:: BioLineRx Ltd.(BLRX)

BL-7040 (IBD) – Received positive results from a Phase 2 proof-of-concept study to evaluate the effectiveness of BL-7040 for the treatment of inflammatory bowel disease (IBD)

Immediate next steps include evaluating the most advantageous ways to progress with this therapeutic candidate from a clinical and business perspective, including examining potential additional indications. Plans also include accelerating discussions with potential co-development and licensing partners.

BL-8040 (AML) – Received U.S. regulatory approvals to commence a Phase 2a trial for the treatment of relapsed/refractory acute myeloid leukemia (AML); trial to be conducted at three sites in the U.S. and five sites in Israel, with initial patient enrollment expected in Q2 2013; partial results expected in Q4 2013 and final results expected in the second half of 2014

BL-1040 (ventricular remodeling) – Recruitment commenced at U.S. sites for the PRESERVATION I clinical trial, a CE Mark registration trial for BL-1040 (BCM), a novel medical device for the prevention of ventricular remodeling following an acute myocardial infarction; there are currently multiple active sites recruiting in six countries

BL-5010 (skin lesions) – Reached final stages of development for proprietary pen-like applicator for BL-5010, a novel formulation of two acids being developed for the non-surgical removal of skin lesions; planning to commence pivotal CE-Mark registration trial for European approval in the second half of 2013

BL-8020 (HCV) – Commenced a Phase 1/2 clinical trial to evaluate the effectiveness of an orally-available, interferon-free treatment for Hepatitis C (HCV) at two sites in France, following approval from the French regulatory authorities; partial results expected in Q4 2013; final results expected in the first half of 2014

BL-1020 (schizophrenia) – Disappointing results of interim analysis for the Phase 2/3 CLARITY trial led to termination of the trial; full unblinded study data is expected during Q3 2013

BL-9010 (severe asthma) – Added a novel, bi-specific antibody for the treatment of severe and persistent asthma to the main therapeutic pipeline, following promising pre-clinical data

Capital Raise – $8 million direct equity placement to the OrbiMed Group was completed in February 2013


“In the past few months, we have seen major progress on a number of clinical and pre-clinical programs in our pipeline, which offer exciting opportunities to address unmet medical needs in a wide range of therapeutic areas. We believe our active programs offer significant potential for patients around the world, as well as for the future success of our Company and its shareholders,” stated Kinneret Savitsky, Ph.D, Chief Executive Officer of BioLineRx. “In the third quarter of this year, we expect to receive a full analysis of the unblinded study data for all participants in the CLARITY Phase 2/3 trial for BL-1020. While we discontinued this clinical trial in mid-March based on disappointing results of the interim analysis, we will not decide the future of the overall BL-1020 program until we have carried out a more thorough review of the full unblinded results.”

“The PRESERVATION I study being conducted by our partner, Ikaria, for BL-1040, for the treatment of ventricular remodeling post-AMI, is moving forward at full steam, with multiple sites in six countries around the world actively recruiting, including a number of sites in the U.S. BL-1040 remains one of our leading compounds, with significant clinical data expected to be reported next year, and we hope that it will eventually offer a great benefit to heart attack patients,” continued Dr. Savitsky.

“We continue to accelerate development of our clinical pipeline, with three of our compounds completing significant milestones since the beginning of the year. Our BL-7040 compound for IBD completed a Phase 2a open-label, proof-of-concept study with very encouraging and positive results. We are now evaluating next steps for BL-7040 in order to identify the best way to move forward from both a clinical and business perspective, including examining potential additional indications. In parallel, we are also planning to accelerate discussions with potential co-development and licensing partners for this asset.”

“In addition, BL-8040, for hematological cancers, one of our most exciting programs, just received FDA approval to commence a Phase 2a trial for the treatment of relapsed/refractory AML. We are excited to initiate this multicenter, open-label study under an IND, which will be conducted in the U.S. and Israel, and will enroll up to 50 patients. MD Anderson Cancer Center in Houston will be the initial site for this trial, with two additional premier sites in the US and five other well-known sites in Israel expected to participate. We believe the excitement surrounding the trial, especially at these particular sites, is a testament to the need for an AML therapy, as well as the potential of BL-8040 shown in the previous pre-clinical and clinical data.”

“Finally, we recently reported enrollment of the first patient in our Phase 1/2 trial for BL-8020, an oral treatment for HCV, at a leading hospital in Paris, France. We look forward to partial results from the trial in the fourth quarter of 2013, as well as final results in the first half of 2014. I would also like to point out that as our pipeline evolves, we continue to replenish our pre-clinical pipeline with the addition of promising assets, such as BL-9010 for the treatment of severe and persistent asthma, which recently graduated from our Early Development Program,” concluded Dr. Savitsky



Link To Interview with BioLineRX VP Of Business Development:
http://www.pharmatelevision.com/Video/1176-PTVNRDavidMalek.aspx



biolinerx.com -  BioLineRX Website




BLRX
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
BLRX News: Report of Foreign Issuer (6-k) 08/15/2017 03:31:34 PM
BLRX News: Report of Foreign Issuer (6-k) 08/08/2017 07:01:34 AM
BLRX News: BioLineRx Reports Second Quarter 2017 Financial Results 08/08/2017 07:00:00 AM
BLRX News: Statement of Beneficial Ownership (sc 13d) 08/08/2017 06:02:43 AM
BLRX News: BioLineRx to Report Second Quarter 2017 Results on August 8, 2017 08/02/2017 07:00:00 AM
News News Alert: Report of Foreign Issuer (6-k) 08/15/2017 03:31:34 PM
PostSubject
#1494   Your numbers are right as of Q2-2017 end https://fintel.io/sob/us/blrx Check Amatuer17 08/16/17 01:02:37 PM
#1493   How do you get 62 million because this dave86 08/16/17 12:54:02 PM
#1492   Just wait for it, Rich. If it Dizzle96 08/16/17 12:31:56 PM
#1491   ya dizzy you better get RICHARDFALZONE1 08/16/17 10:49:06 AM
#1490   There's going to be a massive dump by Dizzle96 08/16/17 09:32:09 AM
#1489   O/ shares are some 101 million Inst hold 62 Amatuer17 08/16/17 06:12:38 AM
#1488   1.13? Dizzle96 08/15/17 11:11:42 AM
#1487   That's true, still as in all midastouch017 08/15/17 12:21:27 AM
#1486   I bought in today at 1.17 looks like dave86 08/14/17 09:59:19 PM
#1485   BioLineRx Ltd. (NASDAQ:BLRX) PT Set at $4.00 by midastouch017 08/14/17 09:08:18 AM
#1484   ValuEngine upgraded BioLineRx from a sell rating to midastouch017 08/11/17 12:42:26 PM
#1483   You were right. 1.14 is support. Dubb10 08/11/17 01:58:25 AM
#1482   You say a lot of stuff. Just statistically zuluwarhelmet 08/10/17 02:13:42 PM
#1480   No I was right! It did hit 1.14 Dizzle96 08/10/17 01:52:43 PM
#1478   Lol, wrong again. midastouch017 08/09/17 04:23:28 PM
#1477   Good posts; thanks Midas. shub 08/09/17 03:26:46 PM
#1476   It'll probably dip to 1.14 Dizzle96 08/09/17 02:39:02 PM
#1475   You'll have another opportunity Dizzle96 08/09/17 02:38:13 PM
#1474   Uhh 1.23 should have added @ 1.03 xzy007 08/09/17 11:27:03 AM
#1473   History repeats itself, especially in the make shift market Dizzle96 08/09/17 08:47:00 AM
#1472   They will run after the pump and dump. Dizzle96 08/08/17 02:50:43 PM
#1471   this is a slow mover...but it should get RICHARDFALZONE1 08/08/17 02:03:43 PM
#1470   BioLineRx's (BLRX) CEO Phil Serlin on Q2 2017 midastouch017 08/08/17 02:01:59 PM
#1469   LOL, i do not see many midastouch017 08/08/17 01:27:23 PM
#1468   BioLineRx Reports Second Quarter 2017 Financial Results midastouch017 08/08/17 08:16:38 AM
#1467   Too bad. You got it wrong again. Up BLRX she goes. midastouch017 08/07/17 03:43:38 PM
#1466   Earnings soon...hoping for a drop.. xzy007 08/07/17 02:35:09 PM
#1465   Buyer beware, the last time zach's put a Dizzle96 08/07/17 09:01:48 AM
#1464   Several hedge funds have recently added to or midastouch017 08/05/17 09:36:13 AM
#1463   BioLineRx Ltd. (NASDAQ:BLRX) Receives $3.62 Consensus Target Price midastouch017 08/05/17 09:34:21 AM
#1462   Partnering In-Licensing midastouch017 08/04/17 01:08:13 PM
#1461   From $0.87 to $1.10 midastouch017 08/04/17 11:32:24 AM
#1460   BioLineRx (NASDAQ:BLRX) initiated midastouch017 08/04/17 09:04:15 AM
#1459   So your math was proven wrong and midastouch017 08/03/17 11:18:23 PM
#1458   There is an actual mathematician here. Thank Dizzle96 08/03/17 06:14:43 PM
#1457   The way normal math works Original price. - $ Amatuer17 08/03/17 04:11:23 PM
#1456   And where are we now ? Lol Dizzle96 08/03/17 03:22:36 PM
#1455   Either way, you're avoiding the main point which Dizzle96 08/03/17 03:20:28 PM
#1454   $100 to $1 is > 100% decline. Who is Dizzle96 08/03/17 03:17:31 PM
#1453   If a stock were to decline from $3 Dizzle96 08/03/17 03:16:34 PM
#1452   From $100 to $1 is less than 100%. ... midastouch017 08/02/17 12:22:24 PM
#1451   You should go back a few years back to midastouch017 08/02/17 12:19:45 PM
#1450   It was trading at over $3 a share Dizzle96 08/02/17 12:15:32 PM
#1449   Look back a few years Dizzle96 08/02/17 12:14:10 PM
#1448   There is no such thing midastouch017 08/02/17 10:52:14 AM
#1447   Run for the hills as fast as you Dizzle96 08/02/17 10:49:00 AM
#1446   BioLineRx to Report Second Quarter 2017 Results on midastouch017 08/02/17 08:04:56 AM
#1445   Presently we are up about 1%...Hardly"Hammered". The sky shub 08/01/17 01:56:59 PM
#1444   Can you really do any verifications midastouch017 08/01/17 09:49:36 AM
#1443   BioLineRx Ltd. (BLRX) is a clinical-stage biopharmaceutical company midastouch017 08/01/17 09:41:40 AM
PostSubject